Welcome to our dedicated page for 111 news (Ticker: YI), a resource for investors and traders seeking the latest updates and insights on 111 stock.
111 Inc. (NASDAQ: YI), China's integrated online/offline healthcare platform, provides this centralized news hub for stakeholders tracking its pharmaceutical e-commerce and digital health services. Access official press releases and verified updates about corporate milestones, financial performance, and strategic initiatives.
This resource delivers timely updates on earnings reports, supply chain innovations, regulatory developments, and partnership announcements. Investors will find essential information about B2B healthcare distribution expansions, B2C retail pharmacy operations, and technological advancements in medical supply chain management.
Content spans operational updates across prescription drug distribution, OTC product launches, digital health service enhancements, and financial disclosures. Regular updates ensure comprehensive tracking of 111 Inc.'s role in transforming China's healthcare ecosystem through tech-enabled solutions.
Bookmark this page for streamlined access to YI's latest corporate communications. Combine these verified updates with Stock Titan's financial tools for informed analysis of this innovative healthcare platform's market position.
111, Inc. (NASDAQ: YI), a tech-enabled healthcare platform company in China, has appointed Grant Thornton Zhitong Certified Public Accountants LLP as its new independent registered public accounting firm. This change, effective July 19, 2024, replaces Deloitte Touche Tohmatsu Certified Public Accountants LLP. The decision was made after careful evaluation and approved by 111's board of directors and audit committee.
Grant Thornton will audit and report on 111's consolidated financial statements for the year ending December 31, 2024, as well as assess the effectiveness of the company's internal control over financial reporting. This change in auditors represents a significant shift in 111's financial oversight and reporting processes.
111, Inc. (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, has announced its participation in a fireside chat with Water Tower Research on July 18, 2024, at 2:00 p.m. ET. The event will feature Junling Liu, Co-Founder, Chairman, and CEO of 111, who will discuss the company's:
- Business model
- Strategic goals
- Competitive landscape and advantages
- Growth drivers
- Market opportunities
The fireside chat is a listen-only event, and interested parties can register using the provided link. A replay will be available on 111's investor relations website under the 'Events' section.
111, a leading tech-enabled healthcare platform, has entered into a strategic partnership with Beijing Scrianen Pharmaceutical to expand nationwide reach and improve drug accessibility. This collaboration will enhance their existing relationship, leveraging big data, digital marketing, and cloud services to make Scrianen's products, including Scrianen Folic Acid Tablets, more accessible both online and offline.
Since 2017, 111 has been a partner in Scrianen's Authentic Alliance. 111 operates an integrated healthcare ecosystem comprising online and offline pharmacies, digital distribution, and SaaS-based services. The partnership aims to utilize both companies' resources to deliver higher-quality healthcare products to a broader audience in China.
111 announced its unaudited financial results for Q1 2024, achieving operational profitability for the first time with an operating income of RMB3.7 million. Net revenues were RMB3.5 billion, down 4.6% YoY due to high demand in Q1 2023. Operating expenses decreased 20.6% to RMB204.8 million, improving operational efficiency. Non-GAAP income rose to RMB8.9 million, a 259.2% increase. However, net loss was RMB2.7 million, down from RMB19.4 million YoY. Cash and equivalents stood at RMB627.3 million. The company plans to increase operational efficiency and market share through technology and cost-saving logistics innovations.
111, Inc. (NASDAQ: YI) will release its unaudited financial results for Q1 2024 on May 23, 2024. The company aims to digitally connect patients with medicine and healthcare services in China. The earnings conference call will take place at 7:30 AM U.S. Eastern Time on the same day.
FAQ
What is the current stock price of 111 (YI)?
What is the market cap of 111 (YI)?
